Press Releases Senti Biosciences, Inc.

Equities

SNTI

US81726A1007

Real-time Estimate Cboe BZX Other stock markets 09:31:17 2024-04-30 am EDT			5-day change	1st Jan Change
0.334 ^USD	+15.17%		+3.24%	-56.06%

Apr. 26	Senti Biosciences, Inc. Announces Resignation of Deborah Knobelman as Chief Financial Officer, Effective May 3, 2024	CI
Apr. 26	Senti Biosciences, Inc. Announces Resignation of Deborah Knobelman as Treasurer and Head of Corporate Development, Effective May 3, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)	08:06am	GL
Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights	Mar. 21	GL
Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program	Jan. 05	GL
Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia	Dec. 22	GL
Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia	Dec. 22	AQ
Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates	Nov. 13	GL
Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China	Nov. 06	GL
Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China	Nov. 06	AQ
Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual Meeting	23-10-31	GL
Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual Meeting	23-10-31	AQ
Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 Meeting	23-09-27	GL
Senti Bio to Participate in Upcoming Conferences	23-09-26	GL
Senti Bio to Participate in Upcoming Investor Conferences	23-09-05	GL
Senti Bio Announces Second Quarter 2023 Results and Pipeline Updates	23-08-11	GL
Senti Bio Announces Second Quarter 2023 Results and Pipeline Updates	23-08-11	AQ
Senti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon Partners	23-08-10	GL
SENTI BIOSCIENCES, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	23-06-23	AQ
Senti Bio Highlights Initial Gene Circuit Data From Collaborations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting	23-05-20	AQ
Senti Bio Highlights Initial Gene Circuit Data From Collaborations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting	23-05-20	GL
SENTI BIOSCIENCES, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	23-05-09	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Senti Biosciences, Inc.

Equities

SNTI

US81726A1007

Press Releases

Filters